These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 33430071)
1. Botulinum Toxin in Movement Disorders: An Update. Anandan C; Jankovic J Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33430071 [TBL] [Abstract][Full Text] [Related]
2. An update on new and unique uses of botulinum toxin in movement disorders. Jankovic J Toxicon; 2018 Jun; 147():84-88. PubMed ID: 28888928 [TBL] [Abstract][Full Text] [Related]
3. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System. Yoshida K Toxins (Basel); 2022 Apr; 14(4):. PubMed ID: 35448891 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin: State of the art. Jankovic J Mov Disord; 2017 Aug; 32(8):1131-1138. PubMed ID: 28639368 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin in movement disorders. Papapetropoulos S; Singer C Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263 [TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin for the treatment of movement disorders. Thenganatt MA; Fahn S Curr Neurol Neurosci Rep; 2012 Aug; 12(4):399-409. PubMed ID: 22661378 [TBL] [Abstract][Full Text] [Related]
15. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193 [TBL] [Abstract][Full Text] [Related]
16. An update on the use of botulinum toxin therapy in Parkinson's disease. Mills R; Bahroo L; Pagan F Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133 [TBL] [Abstract][Full Text] [Related]